Evolution of Coronavirus Disease 2019 (COVID-19) Patients in Extremadura

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

440 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-14

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

At the end of January 2020, the international community was informed of the presence of a new viral disease that started in Wuhan (China) and spread rapidly throughout the world. The identified virus belonged to the coronavirus family (SARS-CoV-2) and the disease was named COVID-19. Today there are more than 2 million people diagnosed in Spain and more than 40 thousand in Extremadura. The partial knowledge about the development, evolution of the affected citizenship and their prognosis both early and late makes it necessary to analyze in depth their global and particular characteristics.

We will carry out a multicenter, observational, descriptive, cross-sectional and longitudinal study of patients diagnosed with SARS-CoV-2 virus infection in the Community of Extremadura to determine the effectiveness of drug treatments and the clinical and evolutionary characteristics of these patients and the different factors that may influence its evolution.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Characteristics and Prognostic Factors of Patients With COVID-19 (Coronavirus Disease 2019)

NCT04569851

COVID-19 Infection

ACTIVE_NOT_RECRUITING

LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION

NCT04409275

Pulmonary Fibrosis

UNKNOWN

Impact of COVID19 on Asthma Patients in Spain

NCT05064501

Asthma Covid19

WITHDRAWN

Impact of COVID-19 on Lung Function in COPD Patients.

NCT05770440

COPD COVID-19

RECRUITING

Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease

NCT04407169

COVID

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Epidemiological, socio-sanitary, clinical, analytical and radiological data will be collected retrospectively and prospectively from all patients diagnosed with COVID-19 without hospital admission in our community from the start of the pandemic and for one year from the start of the study.

These data will be obtained mainly from the clinical history and collected in the data collection notebooks and electronic base designed for the study for subsequent analysis. The data collection period will be one year, estimating a sample of 5,000 patients.

In addition, patients included in the study prospectively will be asked for consent to collect a blood sample for freezing and storage in the Biobank of Extremadura and subsequent use to determine biomarkers and genetics.

The present study will be carried out in accordance with the observational National Post-Authorization Study (EPA) for medicines for human use proposed by Valdecilla Health Research Institute (IDIVAL), the main objective of which is to determine the effectiveness of the pharmacological treatments currently used in COVID-19.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronavirus Disease 2019

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COVID-19 patients

All patients diagnosed with COVID-19 in the community of Extremadura from the beginning of the epidemic to its ending in Spain.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of any age and sex, including minors and pregnant women.
* Patients diagnosed with SARS-Cov2 infection according to the clinical and microbiological criteria established by the Health Authorities and clinical practice (these can be modified based on the Technical document "Clinical management of COVID-19" of the Ministry of Health) who require or not hospitalization and who receive or not specific pharmacologic treatment for the SARS-Cov2 infection.